Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Ratio-Ectosone (00653217). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Betamethasone valerate
Form:
19 of 19 products shown
12 general benefit · 7 not a benefit
Betaderm · DIN 00716618 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Betaderm · DIN 00716618
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1979-12-31 · brand BETADERM CRM 0.05% · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
DIN 00716618: Betaderm
Raw flags: sec3=Y
Item: 840600007; group id 839; item number 2036; lccId None; manufacturer id TAR
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.0596; ministry $0.0596
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716618
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8972Interchangeable products
Betnovate-1/2 · DIN 00011916 · not recorded
Ratio-Ectosone Mild · DIN 00535427 · $0.0596
Shortage status: resolved shortage (ended December 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716618
Shortage record checked October 6, 2026
Ratio-Ectosone Mild · DIN 00535427 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Ectosone Mild · DIN 00535427
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2021-04-14 · brand TEVA-ECTOSONE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.05 % · company Teva canada limited · schedule Prescription
DIN 00535427: Ratio-Ectosone Mild
Raw flags: sec3=Y
Item: 840600007; group id 839; item number 2036; lccId None; manufacturer id RPH
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.0611; ministry $0.0596
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00535427
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4521Interchangeable products
Betaderm · DIN 00716618 · $0.0596
Betnovate-1/2 · DIN 00011916 · not recorded
Shortage status: resolved shortage (ended November 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00535427
Shortage record checked October 6, 2026
Ratio-Ectosone Mild · DIN 00653209 · 0.05% · Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Ectosone Mild · DIN 00653209
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2018-11-02 · brand TEVA-ECTOSONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.05 % · company Teva canada limited · schedule Prescription
Ratio-Ectosone Mild: Formulary list price $0.28 per unit (the source does not state the unit; exact figure $0.2847). What the ministry pays, not the patient.
DIN 00653209: Ratio-Ectosone Mild
Raw flags: sec3=Y
Item: 840600009; group id 839; item number 2038; lccId None; manufacturer id RPH
Source form: Lot; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2847; ministry $0.2847
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00653209
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6822Interchangeable products
Betnovate-1/2 · DIN 02100185 · not recorded
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00653209
Shortage record checked October 6, 2026
Betaderm · DIN 00716642 · 0.05% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Betaderm · DIN 00716642
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1979-12-31 · brand BETADERM ONT 0.05% · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
DIN 00716642: Betaderm
Raw flags: sec3=Y
Item: 840600008; group id 839; item number 2040; lccId None; manufacturer id TAR
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.0596; ministry $0.0596
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716642
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9270Interchangeable products
Betnovate-1/2 · DIN 00012378 · not recorded
Celestoderm-V/2 · DIN 02357879 · $0.0596
Shortage status: resolved shortage (ended July 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716642
Shortage record checked October 6, 2026
Betaderm · DIN 00716626 · 0.1% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Betaderm · DIN 00716626
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1979-12-31 · brand BETADERM CRM 0.1% · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Taro pharmaceuticals inc · schedule Prescription
DIN 00716626: Betaderm
Raw flags: sec3=Y
Item: 840600004; group id 839; item number 2037; lccId None; manufacturer id TAR
Source form: Cr; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.0889; ministry $0.0889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716626
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9268Interchangeable products
Betnovate · DIN 00011924 · not recorded
Celestoderm-V · DIN 02357844 · $0.0889
Ratio-Ectosone Regular · DIN 00535435 · $0.0889
Shortage status: resolved shortage (ended June 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716626
Shortage record checked October 6, 2026
Ratio-Ectosone Regular · DIN 00535435 · 0.1% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Ectosone Regular · DIN 00535435
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2020-07-03 · brand TEVA-ECTOSONE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Teva canada limited · schedule Prescription
DIN 00535435: Ratio-Ectosone Regular
Raw flags: sec3=Y
Item: 840600004; group id 839; item number 2037; lccId None; manufacturer id RPH
Source form: Cr; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.0911; ministry $0.0889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00535435
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4522Interchangeable products
Betaderm · DIN 00716626 · $0.0889
Betnovate · DIN 00011924 · not recorded
Celestoderm-V · DIN 02357844 · $0.0889
Shortage status: resolved shortage (ended February 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00535435
Shortage record checked October 6, 2026
Ratio-Ectosone Regular · DIN 00750050 · 0.1% · Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Ectosone Regular · DIN 00750050
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2018-11-02 · brand TEVA-ECTOSONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Teva canada limited · schedule Prescription
Ratio-Ectosone Regular: Formulary list price $0.31 per unit (the source does not state the unit; exact figure $0.3125). What the ministry pays, not the patient.
DIN 00750050: Ratio-Ectosone Regular
Raw flags: sec3=Y
Item: 840600006; group id 839; item number 2039; lccId None; manufacturer id RPH
Source form: Lot; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.3125; ministry $0.3125
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00750050
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19225Interchangeable products
Betnovate · DIN 02100193 · not recorded
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00750050
Shortage record checked October 6, 2026
Betaderm · DIN 00716650 · 0.1% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Betaderm · DIN 00716650
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1988-12-31 · brand BETADERM ONT 0.1% · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Taro pharmaceuticals inc · schedule Prescription
DIN 00716650: Betaderm
Raw flags: sec3=Y
Item: 840600005; group id 839; item number 2041; lccId None; manufacturer id TAR
Source form: Oint; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.0889; ministry $0.0889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716650
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8973Interchangeable products
Betnovate · DIN 00012386 · not recorded
Celestoderm-V · DIN 02357852 · $0.0889
Shortage status: resolved shortage (ended July 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716650
Shortage record checked October 6, 2026
Betaderm · DIN 00716634 · 0.1% · Scalp Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Betaderm · DIN 00716634
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1979-12-31 · brand BETADERM LOTION 0.1% · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Taro pharmaceuticals inc · schedule Prescription
DIN 00716634: Betaderm
Raw flags: sec3=Y
Item: 840600035; group id 839; item number 2042; lccId None; manufacturer id TAR
Source form: Scalp Lot; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.1271; ministry $0.1271
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716634
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9269Interchangeable products
Valisone · DIN 00027944 · not recorded
Shortage status: resolved shortage (ended March 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716634
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Celestoderm-V/2 · DIN 02357879
Manufacturer: Valeo Pharma Inc.; listing date 2012-04-24
Health Canada: Dormant since 2020-09-29 · brand CELESTODERM V/2 · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.05 % · company Bausch health, canada inc. · schedule Prescription
Celestoderm-V/2: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0596). What the ministry pays, not the patient.
DIN 02357879: Celestoderm-V/2
Raw flags: sec3=Y
Item: 840600008; group id 839; item number 2040; lccId None; manufacturer id VAE
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.0596; ministry $0.0596
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357879
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84297Interchangeable products
Betaderm · DIN 00716642 · $0.0596
Betnovate-1/2 · DIN 00012378 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357879
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 29, 2020 — choose a marketed DIN from the same-category list.
Celestoderm-V · DIN 02357844 · 0.1% · Cr
General benefitDormant since September 29, 2020 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Celestoderm-V · DIN 02357844
Manufacturer: Valeo Pharma Inc.; listing date 2012-04-24
Health Canada: Dormant since 2020-09-29 · brand CELESTODERM V · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Bausch health, canada inc. · schedule Prescription
Celestoderm-V: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0889). What the ministry pays, not the patient.
DIN 02357844: Celestoderm-V
Raw flags: sec3=Y
Item: 840600004; group id 839; item number 2037; lccId None; manufacturer id VAE
Source form: Cr; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.0889; ministry $0.0889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357844
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84293Interchangeable products
Betaderm · DIN 00716626 · $0.0889
Betnovate · DIN 00011924 · not recorded
Ratio-Ectosone Regular · DIN 00535435 · $0.0889
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357844
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 29, 2020 — choose a marketed DIN from the same-category list.
Celestoderm-V · DIN 02357852 · 0.1% · Oint
General benefitDormant since September 29, 2020 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Celestoderm-V · DIN 02357852
Manufacturer: Valeo Pharma Inc.; listing date 2012-04-24
Health Canada: Dormant since 2020-09-29 · brand CELESTODERM V · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Bausch health, canada inc. · schedule Prescription
Celestoderm-V: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0889). What the ministry pays, not the patient.
DIN 02357852: Celestoderm-V
Raw flags: sec3=Y
Item: 840600005; group id 839; item number 2041; lccId None; manufacturer id VAE
Source form: Oint; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.0889; ministry $0.0889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357852
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84294Interchangeable products
Betaderm · DIN 00716650 · $0.0889
Betnovate · DIN 00012386 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357852
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 29, 2020 — choose a marketed DIN from the same-category list.
Betnovate-1/2 · PIN 02100185 · 0.05% · Lot
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Betnovate-1/2 · DIN 02100185
Manufacturer: Roberts Pharmaceutical of Canada Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Betnovate-1/2: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02100185: Betnovate-1/2
Raw flags: notABenefit=Y, sec3=Y
Item: 840600009; group id 839; item number 2038; lccId None; manufacturer id RBT
Source form: Lot; strength: 0.05%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02100185
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Ratio-Ectosone Mild · DIN 00653209 · $0.2847
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02100185
Shortage record checked October 6, 2026
Betnovate-1/2 · DIN 00011916 · 0.05% · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Betnovate-1/2 · DIN 00011916
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1998-07-30 · brand BETNOVATE 1/2 CRM 0.05% · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE VALERATE .05 %/% · company Glaxo canada inc · schedule Prescription
Betnovate-1/2: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00011916: Betnovate-1/2
Raw flags: notABenefit=Y, sec3=Y
Item: 840600007; group id 839; item number 2036; lccId None; manufacturer id GLA
Source form: Cr; strength: 0.05%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00011916
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=170Interchangeable products
Betaderm · DIN 00716618 · $0.0596
Ratio-Ectosone Mild · DIN 00535427 · $0.0596
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00011916
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 1998 — choose a marketed DIN from the same-category list.
Betnovate-1/2 · DIN 00012378 · 0.05% · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Betnovate-1/2 · DIN 00012378
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1998-07-30 · brand BETNOVATE 1/2 ONT 0.05% · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE VALERATE .05 %/% · company Glaxo canada inc · schedule Prescription
Betnovate-1/2: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00012378: Betnovate-1/2
Raw flags: notABenefit=Y, sec3=Y
Item: 840600008; group id 839; item number 2040; lccId None; manufacturer id GLA
Source form: Oint; strength: 0.05%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00012378
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=173Interchangeable products
Betaderm · DIN 00716642 · $0.0596
Celestoderm-V/2 · DIN 02357879 · $0.0596
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00012378
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 1998 — choose a marketed DIN from the same-category list.
Betnovate · DIN 00011924 · 0.1% · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Betnovate · DIN 00011924
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1998-07-30 · brand BETNOVATE CRM 0.1% · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE VALERATE .1 %/% · company Glaxo canada inc · schedule Prescription
Betnovate: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00011924: Betnovate
Raw flags: notABenefit=Y, sec3=Y
Item: 840600004; group id 839; item number 2037; lccId None; manufacturer id GLA
Source form: Cr; strength: 0.1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00011924
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=169Interchangeable products
Betaderm · DIN 00716626 · $0.0889
Celestoderm-V · DIN 02357844 · $0.0889
Ratio-Ectosone Regular · DIN 00535435 · $0.0889
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00011924
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 1998 — choose a marketed DIN from the same-category list.
Betnovate · DIN 02100193 · 0.1% · Lot
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-04-29 — choose a marketed DIN from the same-category list.Discontinued April 29, 2002 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-04-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-04-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Betnovate · DIN 02100193
Manufacturer: Shire Pharma Canada ULC; listing date 1996-10-01
Health Canada: Cancelled post market since 2002-04-29 · brand BETNOVATE LOTION 0.1% · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 % · company Shire pharma canada ulc · schedule Prescription
Betnovate: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02100193: Betnovate
Raw flags: notABenefit=Y, sec3=Y
Item: 840600006; group id 839; item number 2039; lccId None; manufacturer id SHI
Source form: Lot; strength: 0.1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02100193
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=28978Interchangeable products
Ratio-Ectosone Regular · DIN 00750050 · $0.3125
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02100193
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 29, 2002 — choose a marketed DIN from the same-category list.
Betnovate · DIN 00012386 · 0.1% · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Betnovate · DIN 00012386
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1998-07-30 · brand BETNOVATE ONT 0.1% · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE VALERATE .1 %/% · company Glaxo canada inc · schedule Prescription
Betnovate: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00012386: Betnovate
Raw flags: notABenefit=Y, sec3=Y
Item: 840600005; group id 839; item number 2041; lccId None; manufacturer id GLA
Source form: Oint; strength: 0.1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00012386
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=172Interchangeable products
Betaderm · DIN 00716650 · $0.0889
Celestoderm-V · DIN 02357852 · $0.0889
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00012386
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 1998 — choose a marketed DIN from the same-category list.
Valisone · DIN 00027944 · 0.1% · Scalp Lot
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-05-06 — choose a marketed DIN from the same-category list.Discontinued May 6, 2021 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-05-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-05-06 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Valisone · DIN 00027944
Manufacturer: Valeo Pharma Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2021-05-06 · brand VALISONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE VALERATE) 0.1 %/W/W · company Bausch health, canada inc. · schedule Prescription
DIN 00027944: Valisone
Raw flags: notABenefit=Y, sec3=Y
Item: 840600035; group id 839; item number 2042; lccId None; manufacturer id VAE
Source form: Scalp Lot; strength: 0.1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00027944
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1147Interchangeable products
Betaderm · DIN 00716634 · $0.1271
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00027944
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 6, 2021 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D07AC): coverage varies; not interchangeable
Amcinonide (Cyclocort): general benefit, not a benefit
Beclomethasone dipropionate (Propaderm): general benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
Fluocinonide (Lyderm): general benefit, not a benefit
8 more in the class list below
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered
Matched class: 84:06 Anti-Inflammatory
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE
Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE
84:06 Anti-Inflammatory
· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint
· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:06
and 5 more
INDICATIONS AND CLINICAL USE
For the topical management of allergic and inflammatory dermatoses responsive to
corticosteroid therapy. These disorders include: psoriasis, atopic eczema, infantile
eczema, nummular eczema, pruritus ani and vulvae, neurodermatitis (lichen simplex
chronicus), intertrigo, contact dermatitis, seborrheic dermatitis, exfoliative dermatitis,
solar dermatitis, stasis dermatitis and dyshidrosis. Refractory psoriasis may be treated
with Ectosone regular especially in conjunction with the hydration technique of occlusive
dressings.
Page 3
Ectosone mild contains a lower concentration (half strength) of betamethasone and is
indicated for maintenance therapy after the acute phase has been brought under
control, for less severe conditions and for extensive lesions involving large areas of the
body surface.
https://pdf.hres.ca/dpd_pm/00048130.PDF
PM date: November 02, 2018
Source product: TEVA-ECTOSONE; DIN 00535427; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Ratio-Ectosone Mild · DIN 00653209
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00653209
Ratio-Ectosone Regular · DIN 00750050
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00750050
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Betnovate-1/2, Betnovate, Valisone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.